Phase i dose-escalation study of milademetan in patients with relapsed or refractory acute myeloid leukemia

HIGHLIGHTS

• who: Naohiro Sekiguchi from the National Hospital Organization Disaster Medical Center, Tokyo, Japan have published the Article: Phase I dose-escalation study of milademetan in patients with relapsed or refractory acute myeloid leukemia, in the Journal: (JOURNAL)
• what: The authors only assessed the patients with schedule Au2012milademetan was administered once daily on days 1-14 followed by a 14-day rest in a 28-day cycle. The safety results of this study demonstrated that milademetan was well tolerated up to 160 mg in the QD 14/28day schedule without any new safety concerns. The authors . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.